Boston Scientific (NYSE:BSX) Price Target Lowered to $94.00 at Citigroup

Key Points

• Citigroup cut its price target on Boston Scientific to $94 (from $102) but kept a "buy" rating, while the Street consensus remains a Moderate Buy with an average target of $108 reflecting divergent analyst views.
• Shares traded down to $69.17, well below both the 50‑day ($84.03) and 200‑day ($93.98) moving averages, despite a slight quarter beat (EPS $0.80 vs. $0.78) and raised FY‑2026 guidance of $3.43–$3.49.
• Risk signals are elevated: CEO Michael Mahoney sold 160,901 shares (~$15.0M), insider ownership fell ~10.2%, and the stock faces multiple securities‑class actions plus unusually large put‑option activity, increasing potential volatility and litigation risk.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective dropped by investment analysts at Citigroup from $102.00 to $94.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the medical equipment provider's stock. Citigroup's target price suggests a potential upside of 35.90% from the stock's current price.

Other equities analysts have also issued reports about the stock. Mizuho cut their price target on shares of Boston Scientific from $140.00 to $115.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. Argus upgraded Boston Scientific to a "strong-buy" rating in a report on Thursday, February 26th. Oppenheimer lowered their price objective on Boston Scientific from $125.00 to $100.00 and set an "outperform" rating for the company in a research report on Friday, January 16th. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Finally, Barclays decreased their price target on Boston Scientific from $136.00 to $124.00 and set an "overweight" rating for the company in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $108.00.

Boston Scientific Stock Down 1.1%

BSX traded down $0.79 on Wednesday, hitting $69.17. The company had a trading volume of 3,854,330 shares, compared to its average volume of 15,805,073. The stock has a market capitalization of $102.63 billion, a price-to-earnings ratio of 35.70, a P/E/G ratio of 1.01 and a beta of 0.69. The stock has a fifty day moving average price of $84.03 and a 200-day moving average price of $93.98. Boston Scientific has a 12-month low of $68.19 and a 12-month high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analysts' expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company's revenue was up 15.9% compared to the same quarter last year. During the same period last year, the business earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently bought and sold shares of the company. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at $26,000. Steph & Co. acquired a new position in shares of Boston Scientific in the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 170 shares in the last quarter. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter worth about $25,000. Finally, Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Unusually large put‑option activity — traders bought a big volume of puts on BSX (reported 23,040 puts on Monday, ~27% above typical daily put volume), signaling increased bearish bets and hedging demand that can amplify downward pressure on the stock. Investors Buy Large Volume of Put Options on Boston Scientific NYSE: BSX
• Negative Sentiment: Class action(s) filed alleging securities fraud covering purchases between July 23, 2025 and February 3, 2026; multiple firms are soliciting lead‑plaintiff motions with a May 4, 2026 deadline — increasing the risk of litigation costs, settlements or reputational damage. Representative firm notice: Rosen Law Firm (class action and deadline). ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - BSX
• Negative Sentiment: Multiple law firms (Bragar Eagel & Squire, Robbins Geller, Faruqi & Faruqi, Bernstein Liebhard, Levi & Korsinsky, Portnoy, Gross, Frank R. Cruz, Robbins LLP, etc.) are investigating or notifying investors and encouraging claims — the volume of solicitations underscores broad institutional/legal scrutiny and keeps the issue front‑page for investors. Example notice from Bragar Eagel & Squire. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation on Behalf of Long-Term Stockholders
• Negative Sentiment: Ongoing media/legal notices in quick succession (March 9–11) keep uncertainty elevated and may increase volatility; investors concerned about potential earnings/guidance impact from litigation and related disclosures are likely selling or hedging. Example reminder from Faruqi & Faruqi about the May 4 deadline. BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.